Filing identity and reporting period
Important mismatch: The supplied filing is for Trail One, Inc., a Nevada development-stage company, not Citius Pharmaceuticals, Inc. It is a Form 10-Q for the quarter ended March 31, 2014 (the second quarter of Trail One’s fiscal year). The summary below reflects Trail One’s filing and does not provide Citius-specific information.
Business context and financial results
Trail One was developing and marketing customized decorative automobile license-plate tags. It reported no sales or revenue to date and remained a development-stage enterprise.
| Metric | Three months ended March 31, 2014 | Six months ended March 31, 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $9,731 | $10,029 |
| Interest expense | $274 | $341 |
| Net loss | $10,005 | $10,370 |
| Net loss per share, basic and diluted | $0.00 loss per share as presented | $0.00 loss per share as presented |
For the six-month period, operating cash flow was negative $21,008 and financing cash flow was positive $21,008; investing cash flow was zero. Cash was $0 at March 31, 2014. The filing reports no interest or income taxes paid. No gross margin is available because the company reported no revenue.
Financial position and material period-over-period changes
At March 31, 2014, total assets and cash were each $0; current liabilities were $25,054, consisting of $495 accounts payable, $24,207 notes payable, and $352 accrued interest. Working capital and stockholders’ equity were both negative $25,054. Accumulated deficit was $105,586. The notes payable were due on demand and carried a 5% interest rate, according to the note disclosure.
Compared with September 30, 2013, current liabilities and the working-capital deficit increased from $14,694 to $25,054; notes payable increased from $3,200 to $24,207. The six-month net loss improved to $10,370 from $11,649 in the prior-year period, a decrease of $1,279 (about 12%). Operating expenses rose $57, from $9,972 to $10,029, while interest expense fell $1,336, from $1,677 to $341. For the quarter, net loss was $10,005 versus $10,229; operating expenses increased $395 and interest expense decreased $619.
Outlook, risks, and other significant matters
- Management stated that available liquidity was insufficient for at least the next 12 months and that revenue was not expected to cover expenses. It cited an estimated monthly burn rate of about $3,335 and said additional financing was required to fund operations.
- The company disclosed substantial doubt about its ability to continue as a going concern. Management was seeking additional capital, but gave no assurance that equity or debt financing would be available on acceptable terms or at all; failure to obtain funding could force it to cease operations.
- Management was negotiating on a non-binding basis with another business regarding a possible reverse merger. No transaction was assured; a completed transaction could involve issuing shares, a change of control, and assumption of the acquired business’s obligations.
- The company reported ineffective disclosure controls, citing the lack of an independent board or audit committee, inadequate segregation of duties, and reliance on a financial consultant for financial reporting. Management said it planned to address these weaknesses when resources permitted.
- The filing reported no material pending legal proceedings and no material off-balance-sheet arrangements. It stated there had been no change in risk factors since the company’s 2011 Form S-1/A.
Important facts for investors to verify
- Confirm the intended issuer: this filing identifies Trail One, Inc., not Citius Pharmaceuticals, Inc.
- Verify the status and terms of the proposed reverse merger, including any resulting share issuance, control change, or assumed liabilities.
- Assess the company’s ability to secure near-term financing given zero cash, demand debt, a working-capital deficit, and the disclosed going-concern uncertainty.
- Review the stated ineffective disclosure controls and any subsequent remediation.
- Note that the filing’s MD&A describes six-month operating expenses as increasing by $57, but then refers to a “decrease”; the financial statements show an increase from $9,972 to $10,029.